オプションチェーンは、XTI Aerospaceの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、XTI Aerospaceの市場センチメントを評価します。.

XTI Aerospace (NASDAQ:XTIA) 株価情報, オプションチェーン

XTI Aerospace

XTI Aerospace Inc is a development-stage aircraft manufacturer. XTI is developing a vertical takeoff and landing (VTOL) aircraft, the TriFan 600, which is a design-stage six-passenger aircraft that it anticipates will provide point-to-point air travel over distances of up to 700 miles while significantly reducing carbon emissions per mile compared to today's gasoline-powered jet aircraft and helicopters. The TriFan 600 is expected to have a wide usage ranging from private and commercial aviation services for businesses and high-net-worth individuals to emergency medical services (EMS). The Company's operations are located primarily in the United States, Germany, and the United Kingdom.

XTI Aerospace, Inc. Common Stock - Common Stock

XTI Aerospace Inc

Ovintiv's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OVV#NYSE">OVV</a>) short percent of float has risen 9.77% since its last report. The company recently reported that it has 5.45 million shares sold short, which is 2.36% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.38 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Ovintiv Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740403827_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ovintiv has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Ovintiv's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Ovintiv's peer group average for short interest as a percentage of float is 6.81%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Do Investors Really Feel About Ovintiv?

Fabrinet's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) short percent of float has fallen 8.9% since its last report. The company recently reported that it has 1.89 million shares sold short, which is 7.27% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.43 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Fabrinet Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740403822_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Fabrinet has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Fabrinet's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Fabrinet's peer group average for short interest as a percentage of float is 2.53%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is the Market Bullish or Bearish on Fabrinet?

Monster Beverage's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NYSE">MNST</a>) short percent of float has fallen 9.68% since its last report. The company recently reported that it has 21.12 million shares sold short, which is 3.08% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.75 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Monster Beverage Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740403817_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Monster Beverage has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Monster Beverage's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Monster Beverage's peer group average for short interest as a percentage of float is 7.80%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

MNST

Is the Market Bullish or Bearish on Monster Beverage?

Macro Economic Events

News

Econ #s

Economics

Chicago Fed National Activity For January -0.03 Vs 0.18 Prior

Foresight to equip autonomous drones and unmanned aerial vehicles with NVIDIA Jetson Orin platform for enhanced real-time perception, obstacle detection, and energy efficiency across diverse applications
NESS ZIONA, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) ("Foresight" or the "Company"), a leading innovator in 3D perception systems, announces the integration of&nbsp;<a href="https://www.globenewswire.com/Tracker?data=EYnd-9aPlpwAr7IZ7aw2T1DeOrdBb2Q75D0yXrXvT3nKz3L0DrwOCQlTIUpZ1TT6xfvXfOKgfefmhyBw9W5I-yDismNEP95dXHU1zLJTlpL8bColWucGCFIgizN-vHqe7rmjc72vr1cts5lc_esjmQ==">NVIDIA</a><a href="https://www.globenewswire.com/Tracker?data=YMhAtmI-xF5GiSWXq1yhZqwWx9I2OfqyHzG9dtpBZUwTvLgrWjgY6j0rjTWORLqq-HhBTaY021kzZLJLE0SPw-G0h1wG0VLg0NYLgitBavzW-QVm6J9kIiMcBzzVuqwoXuUafOSw4YO5Lssvq9Bcp_LnHPYpldrchx2v8pJSl54="> Jetson Orin</a> computing platforms into its cutting-edge perception technologies.
The collaboration leverages NVIDIA Jetson Orin Nano and NVIDIA Jetson AGX Orin platforms to enhance the capabilities of Foresight's 3D perception systems across various industries, with focus on autonomous drone and unmanned aerial vehicles (UAV).

FRSX

Foresight To Equip Autonomous Drones And Unmanned Aerial Vehicles With NVIDIA Jetson Orin Platform For Enhanced Real-Time Perception, Obstacle Detection, And Energy Efficiency Across Diverse Applications

Piper Sandler analyst Korinne Wolfmeyer maintains Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) with a Neutral and lowers the price target from $173 to $172.

Price Target

Analyst Ratings

Piper Sandler Maintains Neutral on Procter & Gamble, Lowers Price Target to $172

Piper Sandler analyst Korinne Wolfmeyer maintains Kenvue (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) with a Overweight and raises the price target from $24 to $27.

KVUE

Piper Sandler Maintains Overweight on Kenvue, Raises Price Target to $27

Fresh Del Monte Produce Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDP#NYSE">FDP</a>) shares are<a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener"> trading lower in premarket</a> on Monday.
The company reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43907839/fresh-del-monte-produce-inc-reports-fourth-quarter-and-full-fiscal-year-2024-financial-results" rel="noreferrer noopener">fourth-quarter sales growth</a> of 0.4% year-on-year to $1.01 billion, missing the analyst consensus estimate of $1.03 billion.
The increase in net sales was driven by higher net sales in the company&#8217;s fresh and value-added products segment, primarily due to higher per unit selling prices.
Adjusted EPS of $0.26 <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">missed the analyst consensus of $0.37.</a>
Gross profit jumped 9.9% Y/Y to $68.7 million, and the profit margin expanded 60 basis points to 6.8%.
The operating margin was 3%, and operating income for the quarter was $30.3 million versus an operating loss of $113.4 million last year.
Adjusted EBITDA decreased to $35.2 million versus $37.8 million last year. Adjusted EBITDA margin was 3.5%.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43881721/coca-cola-warns-shortage-of-diverse-talent-could-harm-future-success" rel="noreferrer noopener">Coca-Cola Warns Shortage Of Diverse Talent Could Harm Business</a>
The operating cash flow for the twelve months totaled $182.5 million.
The company&#8217;s Board of Directors <a href="https://www.benzinga.com/pressreleases/25/02/b43907584/fresh-del-monte-produce-inc-announces-150-million-share-repurchase-program-and-increases-quarterly" target="_blank" rel="noreferrer noopener">approved an increase in the quarterly</a> dividend from $0.25 to $0.30. The next quarterly dividend will be paid on March 28, 2025, to shareholders of record on March 10, 2025. Additionally, the Board also approved a $150 million share repurchase program
The company held $32.6 million in cash and equivalents as of December 27, 2024. Long term debt as of the end of 2024 decreased to $244.1 million from $400.0 million as of the prior-year end.
&#8220;Our full-year 2024 results reflect the effectiveness of our strategic focus and operational improvements. This success, achieved despite facing several challenges in 2024, was primarily driven by the exceptional performance of our fresh and value-added products segment, particularly pineapples, avocados, and fresh-cut fruit, which continue to fuel our growth and deliver strong gross margins for the Company,&#8221; said Mohammad Abu-Ghazaleh, Fresh Del Monte&#8217;s Chairman and CEO.
Price Action: FDP shares are trading lower by 3.53% at $29.79 in premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43880110/james-bond-franchise-shifts-hands-to-amazon-mgm-studios" target="_blank" rel="noreferrer noopener">James Bond&#8217;s New Era: Amazon MGM Studios Takes Creative Reins of Franchise</a></li>
</ul>
Image via Shutterstock.

Earnings

Guidance

Dividends

Buybacks

Movers

General

Fresh Del Monte Stock Falls As Q4 Sales & Earnings Miss Expectations

Piper Sandler analyst Korinne Wolfmeyer maintains Coty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COTY#NYSE">COTY</a>) with a Overweight and lowers the price target from $9 to $8.

COTY

Piper Sandler Maintains Overweight on Coty, Lowers Price Target to $8

ONEOK, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>) will release its fourth-quarter financial results, after the closing bell, on <a href="https://www.benzinga.com/quote/OKE/earnings">Monday, Feb. 24, 2025</a>.
Analysts expect the Denver, Colorado-based company to report quarterly earnings at $1.04 per share, up from 50 cents per share in the year-ago period. ONEOK projects quarterly revenue of $5.3 billion, compared to $3.96 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Feb. 4, ONEOK announced joint ventures with MPLX to build LPG export terminal in Texas City, Texas.
With the recent buzz around ONEOK, some investors may be eyeing potential gains from the company's dividends too. As of now, ONEOK offers an annual dividend yield of 4.20%, which is a quarterly dividend amount of $1.03 per share ($4.12 a year). &nbsp;
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $142,834 or around 1,456 shares. For a more modest $100 per month or $1,200 per year, you would need $28,547 or around 291 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($4.12 in this case). So, $6,000 / $4.12 = 1,456 ($500 per month), and $1,200 / $4.12 = 291 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
OKE Price Action: Shares of ONEOK fell 0.5% to close at $98.10 on Friday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43891623/top-2-health-care-stocks-that-may-rocket-higher-this-month">Top 2 Health Care Stocks That May Rocket Higher This Month</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Markets

How To Earn $500 A Month From ONEOK Stock Ahead Of Q4 Earnings

On Saturday, Teva Pharmaceuticals Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) and Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug (TEV&#8217;574/SAR447189) for moderate-to-severe ulcerative colitis (UC) and Crohn&#8217;s disease (CD), the two most common forms of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43900182/teva-and-sanofi-present-new-positive-phase-2b-study-results-at-ecco-2025-reinforcing-best-in-class" rel="noreferrer noopener">inflammatory bowel disease (IBD)</a>.
These results were shared at the Congress of the European Crohn&#8217;s and Colitis Organisation.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43601535/axsome-therapeutics-resolves-generic-patent-litigation-with-teva-over-depression-drug-analyst-maintains-axsome-as-top-pick-for-2025" rel="noreferrer noopener">Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As &#8216;Top Pick For 2025&#8217;</a>
Ulcerative colitis
<ul>
<li>In the UC cohort of the RELIEVE UCCD study, 36% (450 mg dose) and 48% (900 mg dose) of patients treated with duvakitug achieved the primary endpoint of clinical remission (mMS) at week 14 compared to 20% treated with placebo.</li>
<li>Placebo-adjusted rates were 16% (450 mg) and 27% (900 mg) (p=0.050 and 0.003, respectively).
<ul>
<li>Higher clinical remission rates were observed for both doses of duvakitug versus placebo in both advanced therapy (AT)-experienced and AT-naïve subgroups of patients.AT-experienced: 29% (450 mg) and 36% (900 mg), with placebo-adjusted rates of 22% (450 mg) and 29% (900 mg).</li>
<li>AT-naïve: 39% (450 mg) and 53% (900 mg), with placebo-adjusted rates of 12% (450 mg) and 26% (900 mg).1-3</li>
</ul>
</li>
</ul>
Crohn&#8217;s disease
<ul>
<li>In the CD cohort of the RELIEVE UCCD study, 26% (450 mg) and 48% (900 mg) of patients with CD treated with duvakitug achieved the primary endpoint of endoscopic response (SES-CD) compared to 13% on placebo.</li>
<li>Placebo-adjusted rates were 13% (450 mg) and 35% (900 mg) at week 14 (p=0.058 and &lt;0.001, respectively).
<ul>
<li>Higher endoscopic response rates were observed for both doses of duvakitug versus placebo in both AT-experienced and -naïve subgroups of patients.AT-experienced: 11% (450 mg) and 48% (900 mg), with placebo-adjusted rates of 7% (450 mg) and 44% (900 mg).</li>
<li>AT-naïve: 47% (450 mg) and 47% (900 mg), with placebo-adjusted rates of 25% (450 mg) and 25% (900 mg).</li>
</ul>
</li>
</ul>
The company expects to start the Phase 3 program in the second half of 2025.
Price Action: TEVA stock is down 0.18% at $16.70, and SNY stock is down 0.48% at $54.20 during the premarket session on last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/02/43901425/apple-bows-out-of-uks-cloud-encryption-amid-governments-backdoor-demands" target="_blank" rel="noreferrer noopener">Apple Bows Out of UK&#8217;s Cloud Encryption Amid Government&#8217;s &#8216;Backdoor&#8217; Demands</a></li>
</ul>
Photo by Ralf Liebhold via Shutterstock

Biotech

Large Cap

Health Care

TEVA

Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease

Stephens &amp; Co. analyst John Campbell maintains Fidelity National Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNF#NYSE">FNF</a>) with a Overweight and raises the price target from $68 to $75.

Stephens & Co. Maintains Overweight on Fidelity National Finl, Raises Price Target to $75

OPTT

Ocean Power Technologies Announces Successful Demonstration Of Defense And Security Capabilities At NAVDEX. Showcasing WAM-V Unmanned Surface Vehicles, Next Generation Powerbuoy, And AI Capable Merrows

Manulife Financial Corporation ("Manulife") announced today that it has&nbsp;entered into an automatic share repurchase plan (the "automatic plan") under which its designated broker will repurchase Manulife's common shares pursuant to its previously announced normal course issuer bid ("NCIB"). The actual number of common shares purchased under the automatic plan, the timing of such purchases and the price at which common shares are purchased will depend upon future market conditions. The automatic plan, which was pre-cleared by the TSX, provides for the potential repurchase of common shares at any time, including when Manulife ordinarily would not be active in the market due to its own internal trading blackout periods, insider trading rules, or otherwise.

Manulife Initiates Automatic Share Repurchase Plan Under Normal Course Issuer Bid; No Terms Disclosed

Stephens &amp; Co. analyst Sudan Loganathan maintains ADC Therapeutics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>) with a Overweight and raises the price target from $6 to $8.

ADCT

Stephens & Co. Maintains Overweight on ADC Therapeutics, Raises Price Target to $8

Piper Sandler analyst Derek Podhaizer maintains Solaris Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEI#NYSE">SEI</a>) with a Overweight and raises the price target from $37 to $50.

Piper Sandler Maintains Overweight on Solaris Energy, Raises Price Target to $50

On Friday, Co-Diagnostics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) withdrew its FDA 510(k) application for its Co-Dx PCR COVID-19 Test on the PCR Pro in favor of submitting an enhanced version of the test <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43895005/co-diagnostics-inc-announces-intention-to-submit-enhanced-version-of-covid-19-test-to-fda-for-510-" rel="noreferrer noopener">for 510(k) clearance</a>.
The company&#8217;s decision to withdraw the submission was based on discussions with the FDA regarding the ability to detect a potential deterioration of one component of the test related to shelf-life stability.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43890231/why-is-cancer-focused-exelixis-stock-trading-higher-on-friday" rel="noreferrer noopener">Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?</a>
Following dialogue with the FDA and exploring the various courses of action available, Co-Dx has determined that the best long-term solution would be to submit an enhanced version of the test to address the matter raised in the 510(k) review process.&nbsp;
After collecting clinical evaluation data to support the new test&#8217;s performance, the company plans to submit the next iteration of the Co-Dx PCR COVID-19 test for 510(k) OTC clearance.
A new submission also allows the company to incorporate more recent&nbsp;Co-Dx PCR platform developments into the COVID-19 test, which Co-Dx believes will help create greater operational and manufacturing efficiencies. For example, it could consolidate manufacturing processes to utilize the next generation of test kits and instruments across all tests on the at-home and point-of-care platform.
The Co-Dx PCR COVID-19 test is expected to be followed by additional tests for tuberculosis, upper-respiratory multiplex, and a multiplex HPV test, among others.
Price Action: CODX stock is down 14.9% at $0.60 during the premarket session on last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43894411/volkswagens-audi-to-grow-north-american-production-report" target="_blank" rel="noreferrer noopener">Volkswagen&#8217;s Audi To Grow North American Production: Report</a></li>
</ul>
Photo by Horth Rasuer via Shutterstock

Penny Stocks

CODX

Penny Stock Co-Diagnostics Withdraws FDA Application For COVID-19 Test, Plans To Submit Enhanced Version

The company's board of directors also authorized an additional share repurchase program of $1.5 billion of the company's common stock. The authorization is effective immediately and is additive to the previous $1.5 billion program authorized on November 3, 2023, which had $194 million remaining authorized and available for repurchase on December 31, 2024.
Since 2017, the company has repurchased $6.7 billion of its common stock, representing 41 percent of its outstanding shares, and has paid cash dividends of $1.7 billion through December 31, 2024. In the last five years, the company continued its meaningful strategic growth, investing $7.1 billion in capital investments and acquisitions, while maintaining a best-in-class, after-tax-return-on-invested capital of 24 percent.&nbsp;

STLD

Steel Dynamics Authorizes An Additional Share Repurchase Program Of $1.5B Of The Company's Common Stock

BACK

Ignite Proteomics, Subsidiary Of IMAC Holdings, Announces MHC-II Expression As Superior Predictor For Pembrolizumab Response Compared To PD-L1 Ahead Of NCCN Conference

Wolfe Research analyst Nigel Coe upgrades Carrier Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) from Peer Perform to Outperform and maintains the price target from $80 to $80.

Upgrades

CARR

Wolfe Research Upgrades Carrier Global to Outperform, Maintains Price Target to $80

Press Releases

XTI Aerospace Adds David Oppenheimer to its Corporate Advisory Board

XTI Aerospace Secures Access to One of the World's Fastest Supercomputers to Accelerate Development of the TriFan 600

Xeriant, Inc. Provides Update on Litigation Against XTI Aircraft Co.

XTI Aerospace Provides Shareholder Update

XTI Aerospace Adds Kimberly Montgomery to its Corporate Advisory Board

XTI Aerospace Announces Key Q1 2025 Product and Engineering Milestones

XTI Aerospace Adds Stephanie Chung to its Corporate Advisory Board

XTI Aerospace's Inpixon Wins the 2025 RTLS Solution of the Year Award

XTI Aerospace Regains Compliance with Nasdaq Listing Requirements

XTI Aerospace Appoints Len Urbas as Senior Vice President of Corporate Development

XERI

XTIA

ARB IOT Group

Brand Engagement Network Inc. - Common Stock

Brand Engagement Network

CISO Global

CLPS

Castellum

CXApp

Global Engine Group Holding Limited - Ordinary Shares

Global Engine Group

Hitek Global Inc. - Class A Ordinary Share

Hitek Global

3 E Network Technology Group Ltd - Class A Ordinary Shares

3 E Network

MicroAlgo

Orangekloud Technology Inc. - Class A Ordinary Shares

Orangekloud Technology

Taoping

Trident Digital Tech Holdings Ltd - American Depository Shares

Comments

XTI Aerospace

XTI Aerospace (XTIA) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル